BioNTech: Vaccine could be shortly tailored to new variants of virus

The corona vaccine developed by the American pharmaceutical firm Pfizer and the German biotechnology firm BioNTech can be more likely to forestall folks from turning into unwell from a mutated variant of the corona virus. There will probably be extra readability about this initially of January, BioNTech CEO Ugur Sahin informed the German information company on Monday DPA.

RNA performs a significant position in vaccine

“We now have already examined the vaccine on about 20 virus variants with different mutations. The immune response created by our vaccine has all the time inactivated all types of the virus,” stated Sahin, additionally a doctor and oncologist.

In response to Sahin, the corona vaccine can in precept be tailored shortly to new variants of the virus.

From a scientific standpoint, Sahin says there are many indications that the Pfizer / BioNTech vaccine can be ready to deal with the mutated coronavirus that’s at the moment circulating in the UK and which has led the Netherlands to an entry ban for vacationers from the UK.

This variant of the virus is barely extra mutated, says Sahin. “We now need to do experimental assessments with it. They may take about two weeks. Nonetheless, we’re assured that the mechanism of motion is not going to be considerably weakened by this.”

Vaccines that medical science has produced till now have been primarily based on the pathogens themselves. Pfizer-BioNTech’s corona vaccine, like that of Moderna, is made with a brand new method wherein so-called messenger RNA (mRNA) performs the main position for the primary time. This comprises genetic data with which, as soon as within the physique, items of the corona virus could be produced.

You can’t get COVID-19 from these items, they trigger the immune system to provide antibodies in opposition to the coronavirus. These antibodies should forestall you from turning into unwell if you happen to come into contact with the corona virus later.

The Netherlands can count on barely extra doses of the Pfizer / BioNTech vaccine within the first quarter of 2021 than beforehand recognized. “We now have agreed to ship 2.49 million doses of vaccine by the top of the primary quarter,” stated Marc Kaptein, medical director of Pfizer Netherlands, on Monday within the broadcast of Information hour. “That is a little more than we first promised.”

Pfizer has a variety of contact with RIVM and the Dutch authorities in regards to the supply of the vaccine and the vaccination program, says Kaptein. “We now have common consultations, for instance tonight. We take a look at what the federal government’s needs are and what can we ship.”

Observe the most recent developments relating to the corona virus in our dwell weblog.



Related Articles